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Aim: The current paper describes a case of prostatic adenocarcinoma metastatic to the skin presenting as an
extrammamary Paget's disease, a very rare and poorly characterised morphological entity. We report a case of
prostatic carcinoma metastatic to skin showing a pattern of extramammary Paget's disease which has not been
clearly illustrated in the literature Case presentation: A 63 year-old man with prostatic adenocarcinoma developed
cutaneous metastases after 16 years. The inguinal metastases were sessile and 'keratotic.' The tumour displayed
solid, glandular areas as well as a polypoid region suggestive of extramammary Paget's disease were identified.
Discussion and conclusions: We review the diagnostic criteria that have led to the correct histopathological
diagnosis in this case. A differential diagnosis of the pagetoid spread in the skin and various forms of cutaneous
metastases determined by a prostatic adenocarcinoma as well as the role of immunohistochemistry in establishing
the prostatic origin are presented in the context of this case. Although, morphologically the cells presented in the
skin deposits were not characteristic for adenocarcinoma of prostate, immunohistochemistry for PSA and PSAP
suggested a prostatic origin.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1395450057455276Introduction
Prostate adenocarcinoma is one of the most common
cancers in Australia. The Melbourne Collaborative Co-
hort Study revealed that 8.4% of the subjects enrolled in
the study developed over 15 years prostatic adenocar-
cinoma and more than 10% of these patients died [1].
While some long-term survivors develop an indolent
disease without dissemination others develop early or
even late metastases. Secondary deposits associated with
prostatic adenocarcinoma are located with predilection
in the bone system while skin metastasis represents an
exceptional event [2]. Evaluation of these skin lesions
should always include a thorough clinical examination,
past history and histopathological evaluation. In some
patients the history of prostatic adenocarcinoma is ab-
sent and in others the histology is not characteristic for
a prostatic origin or the patients might have had cancers* Correspondence: e_petcu@hotmail.com
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reproduction in any medium, provided the orwith various origins. In these cases, immunohistoche-
mistry is an invaluable tool, the most commonly used
markers being prostate-specific antigen (PSA) and pros-
tate acid phosphatase (PSAP) [3]. Skin metastasis deter-
mined by a prostate adenocarcinoma may display a variety
of patterns including the extrammamary Paget’s disease.
However, at the present time, we do not understand the
implication of this morphology for the aggressiveness of
the primary cancer and the general outlook of the patient.Case report
Initially, a 63 year-old male was diagnosed with locally
metastatic prostatic adenocarcinoma, moderately diffe-
rentiated, Gleason score 3 + 3 = 6 (T3NxM0). However,
no prostatectomy was performed after the initial clinical
diagnosis. Subsequently, the patient elected to receive
radiation therapy and long-term flutamide. A bone scan
performed after eight years revealed no proliferative le-
sions. However, at 16 years after the initial diagnosis he
was admitted to dermatology clinic with an eruption of
multiple tan keratotic polypoidal lesions located on his
scalp, abdomen and bilateral groin areas. Bilateral inguinaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Hyperplastic epidermis showing massive infiltration
by “clear cells” suggestive of EMPD.
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http://www.diagnosticpathology.org/content/7/1/106lymphadenopathy was also noted. Clinical and radiological
evaluation revealed an irregularly enlarged prostate. The
MRI showed abdominal lympadenopathy. Several atypical
areas were detected in bone pelvis but a clear diagnosis of
bone metastasis was not possible. However, no other
masses were detected elsewhere. Immediately prior to
his anatomo-pathological evaluation, the patient deve-
loped macroscopic haematuria, overflow urinary inconti-
nence and renal failure with increased creatinine. The
general status of the patient did not allow a prostatic bi-
opsy and the patient was transferred for palliative care and
expired after three weeks. However, during his hospital
stay the PSA level increased from 24.3 ng/ml to 46.3 ng/
ml. A skin biopsy of a fibroepithelial-like lesion located in
the right lower abdominal quadrant (inguinal area) was
performed a diagnosis of skin metastasis was made. His-
topathological evaluation of this lesion revealed several
patterns of metastatic prostatic adenocarcinoma. The do-
minant feature was represented by solid and glandular
areas. In addition, large areas of hyperplastic epidermis re-
vealed clear tumour cells suggestive of extramammary
Paget’s disease (EMPD) (Figure 1; Figure 2).
Discussion
The skin and subcutis represent the site for a large va-
riety of epithelial stromal and lymphovascular tumours
but also metastatic deposits are identified at this site.
Thus metastases from most internal organs and breast
have been described in the skin. The real incidence of skin
metastasis determined by internal organs is difficult to be
ascertained with precision but it seems to be between 2.8
and 5% [4,5]. In this context, prostate adenocarcinomaFigure 1 Skin and subcutis showing hyperplastic epidermis
with “clear cells” suggestive of EMPD. The “shoulder” of the
lesion reveals no epidermal involvement.metastatic to the skin is an exceptional occurrence. Clini-
cal research conducted in 4020 patients with cancer has
revealed 207 cases of metastatic prostate carcinoma but
none of the prostate cancer patients developed skin metas-
tasis [6]. However, it is believed that when noted, skin me-
tastases in patients with prostatic adenocarcinoma are
indicative of a very poor outcome [7] and thorough clinico-
pathological evaluation is mandatory. Rattanasirivilai et al.
[8] mention fewer than 80 published reports of prostate
adenocarcinoma metastatic to the skin between 1962 and
2009. However, a variety of morphological patterns have
been described in the literature (Table 1)
In our reported case, the background where the pros-
tatic cells have lodged was represented by papulo-nodular
skin with preservation of the adnexae (Figure 1). This ob-
vious exophytic pattern was similar to that of fibroepithe-
lial papillomas, melanocytic nevi or warts occurring in
eyelids, neck, axilla or groin. Therefore, we conclude that
a precise macroscopic differential diagnosis and a detailed
personal history are of paramount importance for the
initial clinical diagnosis and work-up. As mentioned, our
patient presented with a mixed pattern of solid and glan-
dular dissemination in the skin but the interesting aspect
was the presence of neoplastic cells in the epidermis sug-
gesting EMPD (Figure 3). These malignant cells present inTable 1 Cutaneous metastasis of prostatic
adenocarcinoma: morphological patterns
 solid/poorly differentiated [9]
 glandular/ductal [10]
 infiltrative [11]
 mucinous with signet ring [12]
 teleangiectatic [13]
 lymphangitic [14]
 with epidermotropism [15]
 with small cell [16]
Figure 3 Malignant cells in epidermis: large, clear and clefted
nuclei with atypical mitoses.
Table 2 Pagetoid spread in the epidermis
A. PRIMARY NEOPLASMS
Paget’s Disease (PD) [17]
 Primary PD
 De novo in the areola [18]
Melanocytic Tumors [19]
 Malignant melanoma [20]
 Spitz’s nevus [21]
 Acral nevus [22]
Epithelial Cutaneous Neoplasms
 Squamous cell carcinoma (Bowen’s disease) [23]
 Extraocular sebaceous carcinoma of the shoulder [24] and left upper
arm [25]
 Ocular sebaceous carcinoma (of Meibomian gland origin) in eyelids
[26,27]
 Merkel cell carcinoma [28]
 Tricholemmal carcinoma [29]
 Porocarcinoma [30]
 Basal cell carcinoma [31]
Benign Epidermal Conditions
 Focal acantholytic dyskeratosis [32]
 Cutaneous hamartoma with pagetoid cells [33]
 Clear cell papulosis of the skin [34,35]
 Pagetoid dyskeratosis of the prepuce [36]
 Benign mucinous metaplasia of the penis (mucosal side of prepuce)
[37]
 Mammary gland-related clear cells of normal nipples (Toker cells)
[38,39]
Lymphohematopoietic Conditions
 Cutaneous T-cell lymphoma
 Pagetoid reticulosis
 Localized Woringer-Kolopp disease [40]
 and generalized Ketron-Goodman disease [41]
 Mycosis fungoides, common type
 Langerhans cell histiocytosis: self-healing [42], malignant [43], nodular
[44]
 Leukemia: Monoblastic leukemia [45]
B. METASTATIC NEOPLASMS
Carcinomas and Malignant Melanoma
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obvious nucleoli and atypical mitoses. Remarkably, some
histological fields showed areas without evidence of
EMPD especially towards the “shoulder” of the sections,
which brings into question the evolution of the lesion
from areas without EMPD to extensive epidermal metas-
tasis regions.
Very importantly, this pattern of prostatic metastasis
needs to be recognised since many other cancers present
similarly and the differential diagnosis could be rather
vast (Table 2).
The currently reported EMPD pattern in a site not
prone to the development of a “primary” extrammamary
Paget’s makes this lesion exceptional. However, the cur-
rently described lesion represents the dissemination from
the initial prostatic adenocarcinoma rather than a “pri-
mary” EMPD. The first argument, upholding this would
be the clinical history. It is likely that dormant neoplastic
foci of prostatic adenocarcinoma have been reactivated.
Subsequently, the patient has developed skin metastases.
Reedy et al. [46] highlight the fact that although rare, the
“primary”extrammamary Paget’s disease is usually seen as
erythematous lesions in areas rich in apocrine glands such
as axilla or perineum. Jones RE et al. [47] concluded in astudy performed on fifty-five patients that in primary
EMPD, the diagnostic criteria are represented by the Paget
cells extending from the epidermis to the epithelial struc-
tures of adnexa, and the dermis. In our case, no lesional
contiguity from the prostate to skin was present. Morpho-
logical changes described in this paper most likely repre-
sent the lymphovascular metastasis originating from the
prostatic gland. One may argue that the aspect of the neo-
plastic cells seen in the epidermis is not that of usual
Figure 4 Malignant cells positive for PSA in both dermis and
epidermis.
Figure 6 Skin and subcutis showing hyperplastic epidermis
with PSAP positive cells. Dermal clusters of neoplastic cells show
PSAP positivity as well.
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pleomorphic variant of prostatic cancer but since there
is no direct link between the prostate and skin lesions,
one may speculate that this patient had two primary
lesions, in the skin and in the prostate. However, this
is not the case and immunohistochemistry was of cru-
cial importance in elucidating the diagnosis. Although,Figure 5 Dermal clusters of malignant cells positive for PSA.
The above epidermis reveals no PSA positive neoplastic cells. Figure 7 Dermal and epidermal PSAP positivity, high power.
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prostatic adenocarcinoma demonstrates positive staining
for PSA. Contrary, some authors have suggested that skin
metastases are negative [48] but in our case the PSA was
intensely positive (Figure 4, Figure 5) for both dermal and
epidermal metastatic cells. Interestingly, in examined tis-
sue, the immunostaining pattern for PSA was displayed as
clumps of brown staining unlike the finely granular stai-
ning classically described in prostatic cells. These findings
raised again the question whether this is truly metas-
tatic prostatic adenocarcinoma. It has been suggested
that rarely several non-prostatic tumors such as salivary
gland neoplasms, malignant melanoma, adenocarcinoma
of paraurethral glands (Skene's), urothelial carcinoma may
show PSA positivity [49]. However, on clinical, CT and
MRI evaluation there was no evidence of any of the above
mentioned tumours in our patient. Therefore, considering
the past history and the current laboratory and histo-
pathological information, the increased serum PSA level
was more likely due to a prostatic adenocarcinoma meta-
static to the skin. In addition, PSAP staining which is
recommended if the PSA staining is not concludent was
intensely positive and revealed neoplastic cells of prostatic
origin in dermis and epidermis (Figure 6, Figure 7). The
rest of immunohistochemistry markers including markers
for neuroendocrine differentiation were non-contributory.
The immunohistochemistry is of paramount importance
in arriving at the correct diagnosis. Srinivasan et al. [50]
have shown that double sequential staining for p63 and
P501S (prostein) is very important to differentiate a pros-
tatic carcinoma from an urothelial primary especially since
some cases of urothelial carcinoma may present with
increased PSA if they involve secondarily the prostate
gland. The sequential method is very useful in circums-
tances when only a limited amount of tissue is available.
Prostein, a 553 amino-acid protein is positive in most of
the prostatic tumours while p63, a transcription factor
belonging to the p53 family is a marker of urothelial dif-
ferentiation. The authors have reported that none of the
urothelial or prostatic cancers evaluated in the study has
shown positivity for both markers. The profile characteris-
tic for urothelial cancers (p63+/p501s-) showed 95.7%
sensitivity, 100% specificity and 100% positive predictive
value while the immunohistochemical profile suggesting a
prostatic origin (p63-/p501s+) showed a 90.2% sensitivity,
100% specificity and also 100% positive predictive value.
[50]. It seems that adenocarcinoma of prostate may
expresses estrogen receptor a (ER-a) in stromal and basal
cells while epithelial cells could express estrogen receptor
b (ER-B) [51]. The authors have revealed that all cases of
low and intermediate grade prostatic adenocarcinoma and
83% of high grade tumours express ER-b. Their study
not only rises the issue of modulation of prostate adeno-
carcinoma by estrogens but also suggest that ER-b mayrepresent a reliable marker which may be used in selected
cases. In difficult cases of metastatic prostatic adenocar-
cinoma, FISH may be the most effective way of reaching
an accurate diagnosis in many types of cancers including
prostate adenocarcinoma [52]. Taylor et al. [53] have
reported that TP53 and PTEN, which may be prostate
cancer tumour suppressors are commonly altered in pros-
tatic adenocarcinoma. The nuclear receptor coactivator
NCOA2 may also be altered in some prostate cancers.
FISH may also identify a narrow deletion on 3p14 which
is associated with TMPRSS2-ERG fusion characteristic
only for prostatic adenocarcinomas. This abnormality may
be described in some cases of TMPRSS2-ERG in parallel
with a PTEN loss [53].
Conclusion
We present a rare pattern of prostatic adenocarcinoma
metastatic to the skin. Immunohistochemistry for PSA
and PSAP along with clinical and radiological examination
and personal history were corroborated for the final diag-
nosis. For the histo/dermatopathologist it is important to
recognize the plethora of various patterns displayed by cu-
taneous metastases of a prostatic adenocarcinoma. Last
but not least, we should be aware that the PSA/PSAP
might not be helpful in confirming the diagnosis if the
skin lesion represents the extension of a poorly differen-
tiated prostatic adenocarcinoma and other markers and/
or methods need to be employed.
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